Nkarta, Inc. (NKTX) Dividend History

Nkarta, Inc. is a biotechnology company focused on developing allogeneic CAR NK (natural killer) cell therapies for cancer treatment. Leveraging its proprietary cell engineering platform, Nkarta aims to create off-the-shelf immunotherapies to improve efficacy and safety for patients with various cancers.

1150 Veterans Boulevard, South San Francisco, CA, 94080
Phone: (925) 407-1049
Website: https://www.nkartatx.com

Dividend History

Nkarta, Inc. currently does not pay dividends

Company News

Nkarta to Participate in an April Investor Conference

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.

GlobeNewswire Inc.
Nkarta to Participate in an Upcoming Investor Conference

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024.

GlobeNewswire Inc.
Nkarta to Participate in Upcoming Investor Conference

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.

GlobeNewswire Inc.
Why Nkarta Stock Is Soaring Today

Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.

The Motley Fool
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President - GlobeNewswire

Nkarta, a biopharmaceutical company, announced changes to its leadership team, including the appointment of Nadir Mahmood as President and the promotion of David R. Shook to Chief Medical Officer and Head of Research & Development.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 03:34:54 UTC